Free Trial
NASDAQ:PRTA

Prothena (PRTA) Stock Price, News & Analysis

Prothena logo
$6.26 -0.21 (-3.25%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$6.64 +0.38 (+6.07%)
As of 07/18/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Prothena Stock (NASDAQ:PRTA)

Key Stats

Today's Range
$6.25
$6.62
50-Day Range
$4.58
$7.61
52-Week Range
$4.32
$25.42
Volume
788,135 shs
Average Volume
808,155 shs
Market Capitalization
$336.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.50
Consensus Rating
Hold

Company Overview

Prothena Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

PRTA MarketRank™: 

Prothena scored higher than 68% of companies evaluated by MarketBeat, and ranked 290th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Prothena has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Prothena has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Prothena's stock forecast and price target.
  • Earnings Growth

    Earnings for Prothena are expected to grow in the coming year, from ($4.04) to ($3.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Prothena is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Prothena is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Prothena has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Prothena's valuation and earnings.
  • Percentage of Shares Shorted

    10.23% of the float of Prothena has been sold short.
  • Short Interest Ratio / Days to Cover

    Prothena has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Prothena has recently decreased by 7.08%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Prothena does not currently pay a dividend.

  • Dividend Growth

    Prothena does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.23% of the float of Prothena has been sold short.
  • Short Interest Ratio / Days to Cover

    Prothena has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Prothena has recently decreased by 7.08%, indicating that investor sentiment is improving significantly.
  • Search Interest

    1 people have searched for PRTA on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Prothena to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Prothena insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.20% of the stock of Prothena is held by insiders.

  • Percentage Held by Institutions

    97.08% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Prothena's insider trading history.
Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

PRTA Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Prothena Announces Corporate Restructuring
PRTA Prothena Corporation plc
See More Headlines

PRTA Stock Analysis - Frequently Asked Questions

Prothena's stock was trading at $13.85 on January 1st, 2025. Since then, PRTA stock has decreased by 54.8% and is now trading at $6.26.

Prothena Corporation plc (NASDAQ:PRTA) issued its quarterly earnings results on Thursday, May, 8th. The biotechnology company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($0.92) by $0.20. Prothena's revenue was up 5500.0% on a year-over-year basis.

Prothena's top institutional investors include Public Employees Retirement System of Ohio (0.08%) and Mogy Joel R Investment Counsel Inc. (0.04%). Insiders that own company stock include William P Scully, Gene G Kinney, Tran Nguyen, Dennis J Selkoe, Richard T Collier, Lars Ekman, Wagner M Zago, Michael J Malecek, Karin L Walker, Hideki Garren, Carol D Karp and Brandon S Smith.
View institutional ownership trends
.

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Prothena investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
5/08/2025
Today
7/19/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PRTA
CIK
1559053
Employees
130
Year Founded
N/A

Price Target and Rating

High Price Target
$81.00
Low Price Target
$6.00
Potential Upside/Downside
+403.2%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.08)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$122.31 million
Net Margins
-79.94%
Pretax Margin
-84.00%
Return on Equity
-21.61%
Return on Assets
-19.32%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.00
Quick Ratio
9.00

Sales & Book Value

Annual Sales
$135.16 million
Price / Sales
2.49
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.05 per share
Price / Book
0.69

Miscellaneous

Outstanding Shares
53,830,000
Free Float
48,875,000
Market Cap
$336.98 million
Optionable
Optionable
Beta
0.01
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:PRTA) was last updated on 7/19/2025 by MarketBeat.com Staff
From Our Partners